|
Targacept slips on mixed results from drug studies
BusinessWeek Shares of Targacept Inc. declined Tuesday after the company said its drug candidate TC-6987 worked as a treatment for asthma in a clinical trial, but failed as a treatment for diabetes. Targacept said asthma patients who were treated with TC-6987 for … Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of … Targacept discontinues two clinical trials, reports success with a third Asthma drug shows promise, diabetes study fails in Targacept phase 2 trials |
View full post on asthma – Google News
